5 Key Takeaways

• 1

  ctDNA testing may help older women with breast cancer avoid surgery by relying on endocrine therapy alone.

• 2

  The study found that persistent ctDNA after 6 months indicated tumor progression, while negative ctDNA at baseline showed no progression.

• 3

  ctDNA serves as a minimally invasive biomarker, allowing for decentralized monitoring through routine blood draws.

• 4

  Pretreatment ctDNA positivity is linked to higher progression risk, suggesting it could enhance traditional pathology markers.

• 5

  If validated, ctDNA testing could lead to more personalized and less invasive breast cancer management strategies.